Trials / Completed
CompletedNCT04547205
A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors
A Phase I, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AK109，an Anti-VEGFR2 Monoclonal Antibody in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first in human(FIH) study to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity and anti-tumor activity of AK109, an anti-VEGFR2 monoclonal antibody, as a single agent in adult subjects with advanced solid tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK109 | AK109, 2#4#8#12#18mg/kg, IV, every 2 weeks (Q2W), or 15 mg/kg every 3 weeks(Q3W) |
Timeline
- Start date
- 2020-06-06
- Primary completion
- 2021-03-24
- Completion
- 2022-10-31
- First posted
- 2020-09-14
- Last updated
- 2023-02-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04547205. Inclusion in this directory is not an endorsement.